
{"id":128208,"date":"2024-11-21T09:02:13","date_gmt":"2024-11-21T08:02:13","guid":{"rendered":"https:\/\/ibecbarcelona.eu\/next-generation-nanomedicine-net-nano\/"},"modified":"2026-05-07T08:23:37","modified_gmt":"2026-05-07T06:23:37","slug":"next-generation-nanomedicine-net-nano","status":"publish","type":"page","link":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/","title":{"rendered":"Next-Generation Nanomedicine (NET-NANO)\u00a0"},"content":{"rendered":"<div class=\"responsive-tabs\">\n<h2 class=\"tabtitle\">Description<\/h2>\n<div class=\"tabcontent\">\n\n\n\n\n<p>Nanomedicine represents a paradigm shift in healthcare, offering tailored and sophisticated diagnostic, imaging, and therapeutic solutions for unmet medical needs. This network unites an interdisciplinary team of 9 IBEC groups, fostering new collaborations to drive translational research with far-reaching societal implications. For this, 4 workshops will be held, covering basic and applied research: \u201cTools to study biological systems\u201d will cover tools (imaging techniques, nanopatterned substrates, functionalized particles) to study biomechanics, cell behaviour, and signalling, relevant to understanding disease; \u201cSelective targeting and biological barriers\u201d will focus on ways to deliver therapies to otherwise inaccessible sites (BBB, lungs, biofilms); \u201cEmerging nanotherapeutic modalities\u201d will explore self-adaptive, stimuli-responsive, and immunomodulatory strategies; \u201cTowards clinical translation\u201d will address challenges and new models to bridge in vitro-to-in vivo and bench-to-clinic gaps. Talks and onsite discussions will ignite ideas, supported by a Teams channel to enable continued contact and lead to project proposals that will be pitched and evaluated in the final retreat.<\/p>\n\n\n\n<p>NET-NANO counts on the participation of the following IBEC research groups:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/ibecbarcelona.eu\/bactinf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Bacterial Infections &amp; Antimicrobial Therapies<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/quasi-living-materials\/\" target=\"_blank\" rel=\"noreferrer noopener\">Bioinspired Interactive Materials and Protocellular Systems<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/cellmolmech\/\" target=\"_blank\" rel=\"noreferrer noopener\">Cellular and Molecular Mechanobiology<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/molecular-bionics\/\" target=\"_blank\" rel=\"noreferrer noopener\">Molecular Bionics<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/nanobioengineering\/\" target=\"_blank\" rel=\"noreferrer noopener\">Nanobioengineering<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/nanoprobes\/\" target=\"_blank\" rel=\"noreferrer noopener\">Nanoprobes &amp; Nanoswitches<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/nanobioelec\/\" target=\"_blank\" rel=\"noreferrer noopener\">Nanoscale bioelectrical characterization<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/nanodevices\/\" target=\"_blank\" rel=\"noreferrer noopener\">Smart Nano-Bio-Devices<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ibecbarcelona.eu\/targeted-therapeutics\/\" target=\"_blank\" rel=\"noreferrer noopener\">Targeted Therapeutics &amp; Nanodevices<\/a><\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Contact us: <\/h5>\n\n\n\n<p>Iris Batalha:&nbsp;<a href=\"mailto:ibatalha@ibecbarcelona.eu\" target=\"_blank\" rel=\"noreferrer noopener\">ibatalha@ibecbarcelona.eu<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<\/div><h2 class=\"tabtitle network-members\">Network Members<\/h2>\n<div class=\"tabcontent network-members-content\">\n\n\n\n\n<h6 class=\"wp-block-heading\"><strong>Network Coordinator<\/strong>:&nbsp;<\/h6>\n\n\n\n<div class=\"wp-block-bcb-team-grid atgb_e3aa8e45  atgb__dcols_3 atgb__tcols_2 atgb__mcols_1\">\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"500\" height=\"544\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Iris-Batalha_2.jpg\" alt=\"\" class=\"wp-image-121698 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Iris-Batalha_2.jpg 500w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Iris-Batalha_2-276x300.jpg 276w\" data-sizes=\"(max-width: 500px) 100vw, 500px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 500px; --smush-placeholder-aspect-ratio: 500\/544;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/molecular-bionics\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm0 7.082c1.602 0 1.792.006 2.425.035 1.627.074 2.385.845 2.46 2.459.028.633.034.822.034 2.424s-.006 1.792-.034 2.424c-.075 1.613-.832 2.386-2.46 2.46-.633.028-.822.035-2.425.035-1.602 0-1.792-.006-2.424-.035-1.63-.075-2.385-.849-2.46-2.46-.028-.632-.035-.822-.035-2.424s.007-1.792.035-2.424c.074-1.615.832-2.386 2.46-2.46.632-.029.822-.034 2.424-.034zm0-1.082c-1.63 0-1.833.007-2.474.037-2.18.1-3.39 1.309-3.49 3.489-.029.641-.036.845-.036 2.474 0 1.63.007 1.834.036 2.474.1 2.179 1.31 3.39 3.49 3.49.641.029.844.036 2.474.036 1.63 0 1.834-.007 2.475-.036 2.176-.1 3.391-1.309 3.489-3.49.029-.64.036-.844.036-2.474 0-1.629-.007-1.833-.036-2.474-.098-2.177-1.309-3.39-3.489-3.489-.641-.03-.845-.037-2.475-.037zm0 2.919c-1.701 0-3.081 1.379-3.081 3.081s1.38 3.081 3.081 3.081 3.081-1.379 3.081-3.081c0-1.701-1.38-3.081-3.081-3.081zm0 5.081c-1.105 0-2-.895-2-2 0-1.104.895-2 2-2 1.104 0 2.001.895 2.001 2s-.897 2-2.001 2zm3.202-5.922c-.397 0-.72.322-.72.72 0 .397.322.72.72.72.398 0 .721-.322.721-.72 0-.398-.322-.72-.721-.72z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=j2xSc9EAAAAJ&amp;hl=en\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Iris Batalha<\/h3><h5 class=\"atgb__member_position\"><em>Senior Researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>She works on developing nanomedicines that target cells through their metabolic phenotypes.<\/em>\u00a0<\/p><\/div><\/div>\n<\/div>\n\n\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n\n\n<p>&nbsp;&nbsp;&nbsp;&nbsp;<br><strong>Network Representatives:&nbsp;<\/strong>&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-bcb-team-grid atgb_41a7d0c2  atgb__dcols_3 atgb__tcols_2 atgb__mcols_1\">\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"400\" height=\"419\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/AnnaLagunas.png\" alt=\"\" class=\"wp-image-121711 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/AnnaLagunas.png 400w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/AnnaLagunas-286x300.png 286w\" data-sizes=\"(max-width: 400px) 100vw, 400px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 400px; --smush-placeholder-aspect-ratio: 400\/419;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/nanobioengineering\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=gtLd2w4AAAAJ&amp;hl=ca\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Anna Lagunas<\/h3><h5 class=\"atgb__member_position\"><em>CIBER-BBN Senior Researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>She works on the interrogation of cells at the nanoscale to gather information on the spatio-temporal regulation of complex biological mechanisms.\u00a0<\/em>\u00a0<\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"300\" height=\"276\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Juan-Fraire.jpg\" alt=\"\" class=\"wp-image-121720 lazyload\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 300px; --smush-placeholder-aspect-ratio: 300\/276;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/nanodevices\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=brOhVKEAAAAJ&amp;hl=es\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Juan Fraire<\/h3><h5 class=\"atgb__member_position\"><em>Senior Researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>He works on exploring the synergy between nanocarriers, advanced light-triggered effects, and cutting-edge enzymatic nanomotors.<\/em><\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"244\" height=\"294\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/NBC_foto.jpg\" alt=\"\" class=\"wp-image-121723 lazyload\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 244px; --smush-placeholder-aspect-ratio: 244\/294;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/bactinf\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=55t6LGwAAAAJ&amp;hl=ca&amp;oi=ao\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">N\u00faria Blanco-Cabra<\/h3><h5 class=\"atgb__member_position\"><em>Postdoctoral researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>She works on innovative antibiofilm therapies, including the use of nanomedicine to target and cross bacterial biofilms.<\/em><\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"1063\" height=\"1417\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Silvia-Muro.jpeg\" alt=\"\" class=\"wp-image-121726 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Silvia-Muro.jpeg 1063w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Silvia-Muro-225x300.jpeg 225w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Silvia-Muro-768x1024.jpeg 768w\" data-sizes=\"(max-width: 1063px) 100vw, 1063px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1063px; --smush-placeholder-aspect-ratio: 1063\/1417;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/targeted-therapeutics\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=--DTkMoAAAAJ&amp;hl=en\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Silvia Muro<\/h3><h5 class=\"atgb__member_position\"><em>Group Leader<\/em><\/h5><p class=\"atgb__member_bio\"><em>She works on the design of nanodevices for delivery of therapeutics to specific disease sites.<\/em>\u00a0<\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"400\" height=\"502\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Galyna-.jpeg\" alt=\"\" class=\"wp-image-121740 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Galyna-.jpeg 400w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Galyna--239x300.jpeg 239w\" data-sizes=\"(max-width: 400px) 100vw, 400px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 400px; --smush-placeholder-aspect-ratio: 400\/502;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/nanoprobes\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=P-Gd_2kAAAAJ&amp;hl=ca\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Galyna Malieieva<\/h3><h5 class=\"atgb__member_position\"><em>Senior researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>She works on the development of new light-activatable nanoswitches for the control of neuronal activity with nanoscale precision for brain circuits studies and innovative neurotherapeutic strategies.\u00a0<\/em>\u00a0<\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"303\" height=\"295\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/AC_photoNanomedicineNetwork-edited.jpg\" alt=\"\" class=\"wp-image-121746 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/AC_photoNanomedicineNetwork-edited.jpg 303w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/AC_photoNanomedicineNetwork-edited-300x292.jpg 300w\" data-sizes=\"(max-width: 303px) 100vw, 303px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 303px; --smush-placeholder-aspect-ratio: 303\/295;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/quasi-living-materials\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?hl=en&amp;user=C6QZc_kAAAAJ\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Adriano Caliari<\/h3><h5 class=\"atgb__member_position\"><em>Postdoctoral Researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>He works on the introduction of specific receptors on xenobiotic membranes to trigger artificial phagocytosis.<\/em>\u00a0<\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"400\" height=\"408\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/1_1907399_Mamatha.jpg\" alt=\"\" class=\"wp-image-121749 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/1_1907399_Mamatha.jpg 400w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/1_1907399_Mamatha-294x300.jpg 294w\" data-sizes=\"(max-width: 400px) 100vw, 400px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 400px; --smush-placeholder-aspect-ratio: 400\/408;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/cellmolmech\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.com\/citations?user=ZkSaE50AAAAJ&amp;hl=en\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Mamatha Nijaguna<\/h3><h5 class=\"atgb__member_position\"><em>Postdoctoral Researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em> She works on the identification of mechanoinhibitors with potential therapeutic applications.\u00a0<\/em>\u00a0<\/p><\/div><\/div>\n\n\n\n<div class=\"wp-block-bcb-team-member bcb__box-shadow\"><div class=\"atgb__member_photo\"><img decoding=\"async\" width=\"400\" height=\"390\" data-src=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Annalisa.jpg\" alt=\"\" class=\"wp-image-121752 lazyload\" data-srcset=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Annalisa.jpg 400w, https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/Annalisa-300x293.jpg 300w\" data-sizes=\"(max-width: 400px) 100vw, 400px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 400px; --smush-placeholder-aspect-ratio: 400\/390;\" \/><div class=\"afgb__social_icons always\">\n<a href=\"https:\/\/ibecbarcelona.eu\/nanobioelec\/\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n\n\n\n<a href=\"https:\/\/scholar.google.it\/citations?user=XwUruU0AAAAJ&amp;hl=en\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"wp-block-bcb-icon\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\"><path d=\"M12 2c5.514 0 10 4.486 10 10s-4.486 10-10 10-10-4.486-10-10 4.486-10 10-10zm0-2c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm-2 10h-2v2h2v6h3v-6h1.82l.18-2h-2v-.833c0-.478.096-.667.558-.667h1.442v-2.5h-2.404c-1.798 0-2.596.792-2.596 2.308v1.692z\"><\/path><\/svg><\/a>\n<\/div><\/div><div class=\"atgb__member_info\"><h3 class=\"atgb__member_name\">Annalisa Cal\u00f2<\/h3><h5 class=\"atgb__member_position\"><em>Senior Researcher<\/em><\/h5><p class=\"atgb__member_bio\"><em>She works on the transformations and nanoscale properties of different functional nanomaterials and on the biophysical characterization of biological entities by scanning probe techniques.<\/em>\u00a0<\/p><\/div><\/div>\n<\/div>\n\n\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n\n\n<\/div><h2 class=\"tabtitle\">Network Programme<\/h2>\n<div class=\"tabcontent\">\n\n\n\n\n<p>NET-NANO will organize 4 day workshops (WS) and a final retreat. Each workshop will feature two distinguished national or international experts and five IBEC speakers. Each WS will feature a \u00abChallenge Board\u00bb to help ignite ideas and interactions, and to provide attendees with a platform to discuss and foster collaboration among groups and with external speakers.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Workshops information<em>.<\/em>&nbsp;&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-gutena-accordion gutena-accordion-block gutena-accordion-block-8366af-d6 is-layout-flow wp-block-accordion-is-layout-flow\" data-single=\"false\">\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h6 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\">Workshop 1: <strong>Tools to study biological systems<\/strong><\/h6>\n<div class=\"trigger-plus-minus\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p style=\"margin-top:0;margin-bottom:0\"><strong>Date and Venue<\/strong><br>Monday 03\/02\/2025 \u00b7 09:00h \u2013 15:45h<br>Dolors Aleu room, Cluster II, Parc Cient\u00edfic de Barcelona (PCB)<br><br>This first workshop will focus on cutting-edge tools and techniques used to investigate cellular processes and disease. The event will feature two plenary lectures by leading external experts, along with a series of presentations by IBEC researchers. &nbsp;<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>09:00 <\/strong>\u2013 <strong>Welcome from Network Coordinator&nbsp;&nbsp;<\/strong><br>&nbsp;<br><strong>09:10<\/strong> \u2013 Marina Giannotti, IBEC group \u201cNanoprobes andNanoswitches\u201d, \u201c<em>Nanomechanics in seek for disease indicators\u201d<\/em><\/p>\n\n\n\n<p><strong>09:40<\/strong> \u2013 Aurora Dols P\u00e9rez, IBEC group \u201cNanoscale Bioelectrical Characterization\u201d, \u201c<em>AFM as a tool for the study of drug delivery systems\u201d<\/em><\/p>\n\n\n\n<p><strong>10:10<\/strong> \u2013 Nisha Pawar, IBEC group \u201cMolecular Bionics\u201d, \u201c<em>Liquid phase Transmission Electron Microscopy and Machine Learning to understand structure and protein aggregation<\/em>\u201d<\/p>\n\n\n\n<p><strong>10:40<\/strong> \u2013 Plenary: Elisabetta Ada Cavalcanti-Adam,University of Bayreuth (Germany), \u201c<em>Surface Nanopatterning for Investigating Receptor Clustering and Crosstalk in Cell Adhesion and Migration\u201d<\/em><\/p>\n\n\n\n<p><strong>11:40<\/strong> \u2013 Coffee Break &amp; Challenge Board &nbsp;<\/p>\n\n\n\n<p><strong>12:10<\/strong> \u2013 Anna Lagunas, IBEC group \u201cNanobioengineering\u201d,\u201c<em>Unveiling membrane protein function with nanotools\u201d<\/em><\/p>\n\n\n\n<p><strong>12:40<\/strong> \u2013 Pau Gorostiza, IBEC group \u201cNanoprobes and Nanoswitches\u201d, \u201c<em>Interprotein charge transfer in respiratory and photosynthetic chains\u201d<\/em><\/p>\n\n\n\n<p><strong>13:10<\/strong> \u2013 Networking Lunch<\/p>\n\n\n\n<p><strong>14:10<\/strong> \u2013 Plenary: Prof Mar\u00eda Garc\u00eda-Parajo, Institute of Photonic Science (ICFO) &amp; Catalan Institute for Research and Advanced Studies (ICREA), \u201c<em>Single molecule imaging tools to unravel spatiotemporal compartmentalisation in living cells<\/em>\u201d<\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\"><strong>15:10<\/strong> \u2013 Roundtable Discussion<br><br><strong>15:40<\/strong> \u2013 Farewell from Network Representatives<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\"><strong>Plenary talks details:<\/strong><br><br><strong>Prof. Elisabetta Ada Cavalcanti-Adam<\/strong>, Chair of Cellular Biomechanics, Faculty of Engineering Science, University of Bayreuth, Germany.<br><\/p>\n\n\n\n<p><strong>Surface nanopatterning for Investigating Receptor Clustering and Crosstalk in Cell Adhesion and Migration<\/strong>&nbsp;<\/p>\n\n\n\n<p>Advances in nanotechnology have provided powerful tools for precisely controlling the physical and chemical microenvironment and for guiding cellular behavior and communication. This talk will explore the use of surface nanopatterning techniques and their functionalization with adhesive ligands to study receptor clustering and its implications for crosstalk in the adhesion and migration of single and collective cells. We aim to elucidate the mechanisms underlying integrin signaling, cadherin-mediated cell-cell junctions, and their interplay during migration. Examples will highlight how these approaches provide understanding of fundamental cell biology and their potential implications in tissue regeneration and cancer metastasis.&nbsp;<\/p>\n\n\n\n<p><em>Prof. Dr. E. Ada Cavalcanti-Adam is currently a full professor for Cellular Biomechanics at the University of Bayreuth, Germany. Education: doctor degree in Dental Medicine from Italy, M.Sc. degree in Biology from University of Pennsylvania (USA) and PhD in Biosciences at Heidelberg University.&nbsp;<br>She was Postdoctoral Fellow and later project leader at the Max Planck Institute for Intelligent Systems in Stuttgart. After completing her Habilitation, from 2017 until 2023 she was research group leader at the Max Planck Institute for Medical Research in Heidelberg and head of the Central Scientific Facility \u201cCellular Biotechnology; she also served as adjunct faculty at the Heidelberg University.&nbsp;<br>In 2004 she received the Marie Curie Intra-European fellowship, in 2008 a fellowship from the \u201eChristiane N\u00fcsslein-Volhardt Foundation\u201c and the Prize \u201eFor Women in Science\u201c. Her research focuses on the mechanobiology of cell adhesion, investigating how cells interact with their physical environment at the molecular level.&nbsp;<\/em><br><\/p>\n\n\n\n<p><strong>Prof. Dr. Mar\u00eda Garc\u00eda-<\/strong><strong>Parajo<\/strong>, Institute of Photonic Science (ICFO) &amp; Catalan Institute for Research and Advanced Studies (ICREA).<\/p>\n\n\n\n<p><strong>Single molecule imaging tools to unravel&nbsp;<\/strong>&nbsp;<strong>spatiotemporal compartmentalisation in living cells&nbsp;<\/strong>&nbsp;<\/p>\n\n\n\n<p>Organisation by compartmentalisation is a general property of natural systems that efficiently facilitates and orchestrates biological events in space and time. Super-resolution microscopy and single molecule dynamic approaches have revealed that compartmentalisation starts at the nanometre scale with molecules organising and interacting transiently with each other following modularity principles. In this talk, I will provide an overview of recent super-resolution and single molecule dynamic approaches ideally tailored to study biological systems with exquisite spatiotemporal resolution. I will describe the combination of multicolour single particle tracking (SPT) at different labelling densities to resolve in real time multi-molecular interactions in living cells. Low density SPT conditions allows to reconstruct the mobility of individual molecules and their transient interactions, while high density conditions provide unique information on the spatial and temporal length scales of cellular regions re-visited (or forbidden) for molecules. We find that molecular diffusion, transient multi-molecular interactions and dynamic re-modelling of the environment play key roles regulating biological function.&nbsp;<\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\"><em>Maria Garcia-Parajo is an ICREA Research Professor at ICFO-Institute of Photonic Sciences, leading the Single Molecule Biophotonics group. Her research focuses on the development of advanced optical techniques to the study of biological processes at the single molecular level on living cells. She obtained her PhD in Physical Electronics in 1993 at Imperial Colleague, UK.&nbsp; Previous experience includes research at L2M-CNRS Paris (France) and University of Twente (The Netherlands). To date she has published more than 200 publications and delivered more than 250 talks at international conferences and workshops upon\u202finvitation. She coordinates several international research projects, and is member of various international scientific advisory, executive and editorial boards. She has received several prestigious awards, including the Young Academy Research fellow award from the Royal Dutch Academy of Sciences (1998), National Prize in Biophysics (2017), Advanced ERC grant (2017) and Emmy Noether Laurate from the European Physical Society (2020). She is co-coordinator of the Winter School in Advanced Microscopy Techniques for the Master in Interdisciplinary Sciences at BIST. Maria is actively involved in (inter)national actions to promote gender equity in Science.&nbsp;<\/em><\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h6 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\">Workshop 2: <strong>Selective targeting and biological barriers<\/strong><\/h6>\n<div class=\"trigger-plus-minus\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p style=\"margin-top:0;margin-bottom:0\"><strong>Date and Venue<\/strong><br>Friday 13\/06\/2025 \u00b7 09:00h \u2013 15:45 h<br>Dolors Aleu room, Cluster II, Parc Cient\u00edfic de Barcelona (PCB)<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>IBEC&#8217;s Next-Generation Nanomedicine Network (NET-NANO) is dedicated to bridging nanomedicine research with practical applications, enhancing our ability to diagnose and treat human diseases effectively. As part of this initiative, a series of thematic workshops are being organised. The second workshop, scheduled for June 13th, will delve into nanomedicine design for selective targeting and overcoming biological barriers. Leading international experts and IBEC researchers will present on topics ranging from nanoparticle design strategies for penetrating barriers like the blood-brain barrier, retina, and bacterial biofilms, to innovative targeting approaches using lipid nanoparticles, multivalent polymeric nanoparticles, and enzymatic nanomotors.<\/p>\n\n\n\n<p><strong><u>Scheduled Program:<\/u><\/strong><\/p>\n\n\n\n<p><strong>09:00\u201309:10<\/strong> \u2013 Welcome from Network Coordinator<\/p>\n\n\n\n<p><strong>9:10\u201309:40<\/strong> \u2013 Prof. Silvia Muro (Targeted therapeutics and nanodevices, IBEC)<br><em>\u201cIsoform-dependent targeting and its relevance for the design of drug delivery strategies\u201d<\/em><\/p>\n\n\n\n<p><strong>09:40\u201310:10<\/strong> \u2013 Dr N\u00faria Blanco-Cabra (Bacterial Infections: Antimicrobial Therapies, IBEC)<br><em>\u201cTargeting and crossing bacterial biofilms with nanomedicine to overcome chronic infections.\u201d<\/em><\/p>\n\n\n\n<p><strong>10:10\u201311:10<\/strong> \u2013 <strong>Plenary:<\/strong> Prof. Katrien Remaut (Ghent University, Belgium)<br><em>\u201cInvestigating and overcoming biological barriers to lipid nanoparticle mediated messenger RNA delivery to the retina\u201d<\/em><\/p>\n\n\n\n<p><strong>11:10\u201311:40<\/strong> \u2013 Coffee Break &amp; Challenge Board<\/p>\n\n\n\n<p><strong>11:40\u201312:10<\/strong> \u2013 Marco Basile (Molecular Bionics, IBEC)<br><em>\u201cMultivalent Nanoparticles as Modulators of the Blood\u2013Brain Barrier: A New Paradigm for Superselective Nanomedicine\u201d<\/em><\/p>\n\n\n\n<p><strong>12:10\u201312:40<\/strong> \u2013 Dr David Esporr\u00edn Ubieto (Smart Nano-Bio-Devices, IBEC)<br><em>\u201cEnzymatic nanomotors with enhanced motion in viscous media for advanced biomedical applications\u201d<\/em><\/p>\n\n\n\n<p><strong>12:40\u201313:10<\/strong> \u2013 Dr S\u00edlvia Pujals (IQAC-CSIC and IBEC)<br><em>\u201cSuper resolution methods for nanomedicine\u201d<\/em><\/p>\n\n\n\n<p><strong>13:10\u201314:10<\/strong> \u2013 Networking Lunch<\/p>\n\n\n\n<p><strong>14:10\u201315:10<\/strong> \u2013 <strong>Plenary:<\/strong> Pablo Scodeller (Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Spain)<br><em>\u201cIdentifying targeting peptides and biomarkers using phage-display\u201d<\/em><\/p>\n\n\n\n<p><strong>15:10\u201315:40<\/strong> \u2013 Roundtable Discussion<\/p>\n\n\n\n<p><strong>15:40\u201315:45<\/strong> \u2013 Farewell from Network Representatives<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Prof<\/strong>. <strong>Katrien Remaut<\/strong>, Ghent University<br><br><strong>Investigating and overcoming biological barriers to lipid nanoparticle mediated messenger RNA delivery to the retina<\/strong><br><br>Lipid nanoparticle (LNP) mediated messenger RNA delivery to the retina has potential to treat a variety of retinal disorders by the transient expression of proteins, benefitting those applications that require short-term intracellular protein expression such as reprogramming or genome editing. Efficient delivery of mRNA to the retina remains however a major bottleneck. In short, LNPs should encapsulate sufficient amounts of mRNA, protect mRNA against degradation, be mobile in the vitreous and migrate over the inner limiting membrane (ILM) to reach the retinal cells. Furthermore, LNPs should be taken up in the desired cell type and avoid immune recognition during all steps of the delivery pathway. This lecture will discuss several extracellular and intracellular barriers encountered after intravitreal or subretinal injection of LNPs and the ex vivo models that were developed to study them.<br><br><em>Katrien Remaut is an associate professor at Ghent University with expertise in ocular drug delivery barriers. She is the author and co-author of numerous peer-reviewed publications in journals such as Advanced Drug Delivery Reviews, Biomacromolecules, Journal of Controlled Release, ACS Nano, and Nature Biotechnology.<\/em> <em>She has received several scientific awards, including the Prize of the Royal Academy of Medicine for Scientific Research in Pharmacy for the best PhD thesis (2008\u20132011). In 2013, she was elected as a member of the Young Academy in Flanders. Katrien teaches biochemistry to second-year pharmacy students at the Faculty of Pharmacy, Ghent University, consistently earning excellent student evaluations.<\/em><br><em>She serves as Associate Editor at the European Journal of Pharmaceutics and Biopharmaceutics and sits on the editorial board of the Journal of Controlled Release. Her main research interests include ocular delivery of nucleic acids such as messenger RNA, siRNA, and antisense oligonucleotides. She employs advanced fluorescence microscopy methods to study the physicochemical properties and biological barriers affecting non-viral nanoparticles. Her current work focuses on developing lipid nanoparticles (LNPs) for efficient, safe, and non-immunogenic mRNA delivery to the retina.<\/em><br><br><strong>Dr. Pablo Scodeller<\/strong>, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC)<br><br><strong>Identifying targeting peptides and biomarkers using phage-display<\/strong><br><br>Diseased vasculature and tissue can be probed very finely using <em>in vivo<\/em> phage-displayed peptide libraries. This methodology allows the identification of peptides that reach the tissue of interest and bind to proteins in their native disease-specific environment and conformation. Since its introduction in 1996, this technology has led to the discovery of various targeting peptides, some of which are now in advanced clinical trial stages. Over the last decade, using this powerful approach, we have identified a diverse array of targeting peptides specific to brain injuries, Alzheimer\u2019s disease, tumor-associated macrophages, and glioblastoma. Importantly, receptor identification for these peptides has revealed unexpected molecular alterations in the vasculature of Alzheimer\u2019s and glioblastoma, constituting novel biomarkers.<br>This talk will describe how these peptides are identified and used to deliver drugs to tumor-associated macrophages in breast cancer, to glioblastoma, and present new evidence for a novel glioblastoma biomarker.<br><br><em>Dr. Pablo Scodeller earned a degree in Biomedical Engineering from the University of Mendoza (Argentina) in 2005. He pursued a PhD in Chemistry at the University of Buenos Aires, focusing on electrochemistry and nanobiosensors, which he completed in 2011. He followed this with a postdoctoral fellowship in Materials Science, studying silica nanoparticles for biomedical applications. In 2013, he joined the lab of Dr. Erkki Ruoslahti (2022 Lasker Prize Laureate) in La Jolla, USA, for postdoctoral research on the tumor microenvironment. Two years later, he moved to the University of Tartu, Estonia, to work with Dr. Tambet Teesalu, a pioneer in tumor-penetrating peptides. In 2017, he received a Starting Grant from the Estonian Research Council, and in 2018, he was promoted to Associate Professor. In 2021, he was awarded a prestigious <strong>Ram\u00f3n y Cajal<\/strong> contract in Spain.<br>Dr. Scodeller has published 33 scientific articles, including first or co-first authorship in JACS and Nature Communications. His h-index is 22 with ~2,000 citations. He is co-inventor of 4 granted and licensed patents related to targeting peptides for cancer, brain injuries, and Alzheimer\u2019s disease, and holds a pending patent on a peptide-drug conjugate for reprogramming tumor macrophages. He has been awarded five research projects as Principal Investigator, totaling over \u20ac500,000, and has supervised or is supervising 2 doctoral theses and 5 master&#8217;s theses.<\/em><br><br><strong>Dr. Silvia Muro<\/strong>, IBEC \u2013 ICREA<br><br><strong>Isoform-dependent targeting and its relevance for the design of drug delivery strategies<\/strong><br><br>Drug targeting aims to increase the site-specificity of therapeutics, often by coupling drugs or carriers to affinity molecules that recognize specific protein targets at disease sites. However, a long-overlooked challenge is that approximately 95% of these protein targets are not expressed as a single entity, but rather as multiple isoforms. As a result, targeting molecules may fail in clinical trials due to poor isoform specificity.<br>By identifying the specific isoforms expressed by certain cell types or under particular disease conditions, it becomes possible to design more robust and effective targeting molecules. This concept of <strong>isoform-dependent targeting<\/strong> introduces a new and highly relevant paradigm in the field of drug delivery.<br><br><em>Dr. Silvia Muro earned her PhD in Sciences from Universidad Aut\u00f3noma de Madrid. She then moved to the United States, first joining the University of Pennsylvania and later the University of Maryland, where she achieved tenure in 2012. Since 2017, she has been an ICREA Professor at the Institute for Bioengineering of Catalonia (IBEC). Her research lies at the intersection of <strong>cellular biology and drug delivery<\/strong>, focusing on the biological mechanisms that govern cargo transport within cells and tissues. She leverages this understanding to develop targeted therapeutic strategies, particularly those involving <strong>intra- and trans-cellular transport<\/strong>. Dr. Muro has authored over 100 scientific publications, holds licensed patents, and serves on the editorial boards of several scientific journals. Her work has earned her prestigious awards from the Controlled Release Society and the American Society for Nanomedicine. She is also a <strong>Fellow of the American Institute for Medical and Biological Engineering (AIMBE).<\/strong><\/em><br><br><strong>Dr. David Esporr\u00edn Ubieto<\/strong>, Institute for Bioengineering of Catalonia (IBEC)<br><br><strong>Enzymatic nanomotors with enhanced motion in viscous media for advanced biomedical applications<\/strong><br><br>Targeted drug delivery remains a significant challenge in biomedical research, particularly due to the difficulty of navigating through highly viscous biological fluids such as mucus and synovial fluid. A promising solution lies in self-propelled nanoparticles, or <strong>nanomotors (NMs)<\/strong>, which can actively move through these complex environments. Silica-based NMs have been extensively studied for their established synthesis protocols, yet their high density and low water solubility limit their effectiveness in biological contexts. This presentation explores the shift toward <strong>next-generation organic nanomotors<\/strong>, specifically <strong>responsive nanogels<\/strong>\u2014chemically cross-linked polymer networks that adapt their size and hydrophilicity in response to environmental cues like pH, temperature, and redox conditions. These properties greatly improve NM mobility in viscous media, reduce unwanted interactions with surrounding tissues, and enhance their biomedical utility. The talk will cover their design, synthesis, in vitro performance, and in vivo imaging applications.<br><br><em>Dr. David Esporr\u00edn is a postdoctoral researcher at the Institute for Bioengineering of Catalonia (IBEC), under the supervision of Prof. Samuel S\u00e1nchez, and also serves as a lecturer at the International University of Catalonia (UIC). His research centers on the <strong>development of organic-based nanomotors<\/strong> with superior <strong>biocompatibility, degradability, and mobility<\/strong> for targeted biomedical applications. He earned his PhD at <strong>POLYMAT (University of the Basque Country, San Sebasti\u00e1n)<\/strong> under the supervision of Prof. Marcelo Calder\u00f3n, focusing on polymeric gel systems for ocular drug delivery and protein interactions. Prior to that, he conducted graduate research at the <strong>Institute of Nanoscience and Materials of Arag\u00f3n (INMA)<\/strong> in the group of Prof. Jes\u00fas Mart\u00ednez de la Fuente, where he worked on peptide-based nanocarriers for targeted drug delivery. His recent research includes enhancing the stability and photothermal performance of gold nanoparticles and developing organic nanomotors that can traverse biological barriers. His work has been published in top-tier journals like Small and ACS Nano, and presented at international conferences and science outreach events.<\/em><br><br><strong>Dr. S\u00edlvia Pujals Riat\u00f3s<\/strong>, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC)<br><br><strong>Super resolution methods for nanomedicine<\/strong><br><br>We employ <strong>advanced microscopy techniques<\/strong> to visualize and track <strong>self-assembled nanomaterials<\/strong> with therapeutic potential. Understanding the interaction between these materials and cells is essential for developing novel nanotechnology-based therapies aimed at <strong>cancer<\/strong> and <strong>infectious diseases<\/strong>. Our work focuses on innovative bioactive materials such as <strong>nanoparticles<\/strong> and <strong>peptide-based nanofibers<\/strong>. To investigate their behavior in biological environments, we utilize a variety of <strong>optical microscopy<\/strong> methods, with particular emphasis on <strong>super resolution microscopy (SRM)<\/strong>, capable of achieving resolution down to <strong>5 nm<\/strong>. We demonstrate how techniques like <strong>STORM<\/strong> and <strong>PAINT<\/strong> allow us to image nanomaterials beyond the diffraction limit. SRM enables us to trace the journey of nanomaterials inside the body\u2014from <strong>protein corona formation<\/strong>, through <strong>extravasation and targeting<\/strong>, to <strong>intracellular tracking<\/strong>. Furthermore, we have developed a <strong>correlative light and electron microscopy<\/strong> method that supports a <strong>multiparametric analysis<\/strong> of nanoparticles within cells.<br><br><em>Dr. S\u00edlvia Pujals is a <strong>tenured researcher<\/strong> at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC). She earned her <strong>PhD in Organic Chemistry<\/strong> from the <strong>University of Barcelona (UB)<\/strong>, specializing in <strong>cell-penetrating peptides<\/strong>. She then completed her postdoctoral research at <strong>Kyoto University<\/strong>, focusing on <strong>biophysics and electron microscopy<\/strong>. Her scientific expertise spans <strong>drug delivery<\/strong>, <strong>peptide synthesis<\/strong>, and both <strong>optical and electron microscopy<\/strong>. Throughout her career, Dr. Pujals has concentrated on the design and study of advanced drug delivery systems. Her <strong>chemistry background<\/strong> is key to developing more efficient and selective delivery platforms, while her skills in <strong>microscopy<\/strong> enable in-depth characterization using <strong>super-resolution<\/strong> and <strong>correlative microscopy<\/strong> approaches.<\/em><strong><br><\/strong><br><strong>Dr. N\u00faria Blanco-Cabra<\/strong>, Institute for Bioengineering of Catalonia (IBEC)<br><br><strong>Targeting and crossing bacterial biofilms with nanomedicine to overcome chronic infections<\/strong><br><br><strong>Bacterial biofilms<\/strong> are a defining feature of chronic infections due to their structural and physiological resistance to antimicrobials. Their <strong>dense extracellular matrix<\/strong> and altered microenvironment drastically reduce drug penetration and effectiveness. <strong>Nanomedicine<\/strong> presents a promising strategy to overcome these limitations by enabling: targeted antimicrobial delivery,enzymatic disruption of the biofilm matrix, Enhanced diffusion of therapeutic agents. This talk will present <strong>recent advances<\/strong> in <strong>multifunctional nanoparticle systems<\/strong> designed to <strong>breach the biofilm barrier<\/strong>. It will also include a <strong>critical analysis<\/strong> of their translational potential and the <strong>key challenges<\/strong> that must be addressed to move these technologies toward <strong>clinical application<\/strong>.<br><br><em>N\u00faria earned her PhD in Biomedicine from the University of Barcelona (UB) in 2021. During her doctoral studies, she collaborated with over five nanomaterial groups to pioneer new strategies for combating bacterial biofilms using nanomedicine. In 2022, she undertook a postdoctoral placement with Peter Sass&#8217;s group at the University of T\u00fcbingen, Germany. Following this, in 2023, she joined Dr. Eduard Torrents&#8217; group at IBEC. Currently, N\u00faria is a postdoctoral researcher in the Bacterial Infections &amp; Antimicrobial Therapies group at IBEC, where she leads the research of innovative antibiofilm therapies, including the use of nanomedicine to target and cross bacterial biofilms. She is coauthor of 20 peer-reviewed scientific publications with an h-index of 13.<\/em><br><br><strong>Marco Basile<\/strong>, Institute for Bioengineering of Catalonia (IBEC)<br><br>\u2018<strong>Multivalent Nanoparticles as Modulators of the Blood\u2013Brain Barrier: A New Paradigm for Superselective Nanomedicine<\/strong>\u2019<br><br>Neurodegenerative diseases like Alzheimer\u2019s pose major treatment challenges, partly due to the blood-brain barrier (BBB) limiting drug delivery. The BBB\u2019s receptor-mediated transport is key for clearing harmful proteins from the brain. This study explores biodegradable nanoparticles designed with controlled ligand density to enhance selective interactions with BBB receptors. By tuning nanoparticle avidity, we promote targeted transport across brain endothelial cells. In vitro assays showed specific binding and improved permeability, while gene and protein analyses indicated modulation of BBB markers. Investigations of receptor dynamics revealed new insights into pathways involved in protein clearance. Our results highlight the potential of multivalent nanoparticles to selectively enhance receptor-mediated BBB transport, offering a promising approach to develop nanomedicines for neurodegenerative disorders.<br><br><em>Marco Basile completed his Bachelor\u2019s and Master\u2019s degrees in Pharmaceutical and Health Biotechnologies at the University of Naples Federico II, where he began his research career working on lipid-based and polymeric nanoparticle systems. Supported by an Erasmus+ fellowship, he further expanded his scientific training at IBEC, University of Barcelona, contributing to projects focused on nanoparticle interactions with biological barriers. Currently, Marco is pursuing a PhD in Neuroscience at IBEC\u2013University of Barcelona, funded by the \u201cla Caixa\u201d Foundation. His research centers on elucidating the mechanisms by which misfolded proteins, particularly amyloid-\u03b2 assemblies, behave at the blood\u2013brain barrier. Moreover, by designing multifunctional nanoparticle systems and developing robust in vitro models of the blood\u2013brain barrier, Marco aims to better understand transcytosis pathways and their modulation in neurodegenerative diseases. His work seeks to provide new insights that can advance the development of targeted therapeutic strategies for conditions such as Alzheimer\u2019s disease<\/em>.<br><br><br><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h6 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\">Workshop 3: <strong>Emerging nanotherapeutic modalities<\/strong><\/h6>\n<div class=\"trigger-plus-minus\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p style=\"margin-top:0;margin-bottom:0\"><strong>Date and Venue<\/strong><br>Friday 19\/09\/2025 \u00b7 08:45h \u2013 15:45 h<br>Dolors Aleu room, Cluster II, Parc Cient\u00edfic de Barcelona (PCB)<br><br><\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\">The <strong>Next-Generation Nanomedicine Network (NET-NANO) <\/strong>is hosting its third workshop on <strong>September 19<sup>th<\/sup><\/strong>, focusing on <strong>emerging nanotherapeutic modalities<\/strong>. This event will explore the latest advancements in self-adaptive, stimuli-responsive, and immunomodulatory strategies for nanomedicine. The workshop will feature talks from both internal IBEC researchers and leading external experts, including plenary sessions by <strong>Prof. H\u00e9lder A. Santos<\/strong>, <strong>Prof. V\u00edctor F. Puntes<\/strong>, and <strong>Associate Prof. Cristina Fornaguera<\/strong>. Join us for a day of insightful presentations, a challenge board, and a roundtable discussion to network and explore the future of nanomedicine.&nbsp;<br><br><strong><u>Scheduled Program:<\/u><\/strong><br><br><strong>08:45-09:00<\/strong> \u2013 Registration<br><br><strong>09:00-09:10<\/strong> &#8211; Welcome from Network Coordinator<br><br><strong>09:10-09:40<\/strong> &#8211; Ekin Opar (Nanoprobes and Nanoswitches, IBEC)<br><em>\u201cTriplet-Sensitized Photopharmacology for Deep Tissue Modulation of Cardiac Activity\u201d<\/em><br><br><strong>09:40-10:10<\/strong> &#8211; B\u00e1rbara Borges Fernandes (Molecular Bionics, IBEC)<br><em>\u201cChemotactic Liposomes as Minimal Models of Active Navigation\u201d<\/em><br><br><strong>10:10-11:10<\/strong> &#8211; Plenary: Prof. H\u00e9lder A. Santos (University Medical Center Groningen, The Netherlands)<br><em>\u201cRNA-Based Polysaccharide Nanoformulations for Myocardium Infarction Therapy\u201d<\/em><br><br><strong>11:10-11:40<\/strong> &#8211; Coffee Break &amp; Challenge Board<br><br><strong>11:40-12:10<\/strong> &#8211; Dr. Juan C. Fraire (Smart Nano-Bio-Devices, IBEC\/ IQAC-CSIC \u2013 Institute for Advanced Chemistry of Catalonia)<br><em>\u201cCombining Nanocarrier Design and Self-Propulsion for Delivery of Nucleic Acids\u201d<\/em><br><br><strong>12:10-13:10<\/strong> &#8211; Plenary: Prof. V\u00edctor F. Puntes (ICN2 \u2013 Institut Catal\u00e0 de Nanoci\u00e8ncia i Nanotecnologia\/ VHIR \u2013 Vall d&#8217;Hebron Institut de Recerca, Spain)<br><em>\u201cDoping Cerium Oxide Nanocrystals with Oxygen Vacancies to Regulate Mitochondrial Function in the Context of Immune Exhaustion, Loss of Immunosurveillance and Cancer Development\u201d<\/em><br><br><strong>13:10-14:10<\/strong> &#8211; Networking Lunch<br><br><strong>14:10-15:10<\/strong> &#8211; Plenary: Associate Prof. Cristina Fornaguera (IQS \u2013 Institut Qu\u00edmic de Sarri\u00e0\/ URL &#8211; Universitat Ramon Llull, Spain)<br><em>\u201cOvercoming Biological Barriers: RNA Delivery via Poly(\u03b2-amino ester) Nanocarriers\u201d<\/em><br><br><strong>15:10-15:40<\/strong> &#8211; Roundtable Discussion<br><br><strong>15:40-15:45<\/strong> &#8211; Farewell from Network Representatives<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Ekin Opar,<\/strong> Institute for Bioengineering of Catalonia (IBEC), Nanoprobes and Nanoswitches Group<br><br><strong>Triplet-Sensitized Photopharmacology for Deep Tissue Modulation of Cardiac Activity<\/strong><br><br>Photopharmacology offers remote control of protein targets using light. However, conventional photoisomerization is limited by tissue scattering and penetration. In this talk, I will present a nanotherapeutic strategy that overcomes this challenge using triplet-sensitized photoisomerization of a photoswitchable ligand (PAI) targeting M2 muscarinic receptors. By combining PAI with Zinc Phthalocyanine (ZnPc), a triplet sensitizer absorbing at 730 nm, we achieved robust photoactivation in deep tissues under low-power infrared light. I will discuss the experimental implementation in <em>Xenopus<\/em> tadpole heart models and highlight the broader implications of photon-mediated therapeutic modulation. This approach supports a new generation of minimally invasive, light-controllable therapies that operate in the phototherapeutic window.<br><br><em>Ekin Opar is a PhD candidate in the Nanoprobes and Nanoswitches Group at IBEC (Barcelona), working under the supervision of Prof. Pau Gorostiza. With a background in physics and biomedical optics, her earlier research during her MSc involved the design of an ultrafast ablation endoscope for minimally invasive applications. Currently, her doctoral work focuses on light-controlled pharmacological tools and their implementation in neuroscience. She works on photon-mediated stimulation platforms, including multiphoton, upconversion-assisted photoisomerization and triplet-sensitized photoisomerization. Ekin has led in vivo studies using photoswitchable ligands combined with infrared-sensitive sensitizers to enable deep tissue modulation of neural and cardiac activities. Her work contributes to bridging optical technologies with translational photomedicine.<\/em><br><br><br><strong>B\u00e1rbara Borges Fernandes<\/strong>, Institute for Bioengineering of Catalonia (IBEC), Molecular Bionics group, and University of Barcelona<br><br><strong>Chemotactic Liposomes as Minimal Models of Active Navigation<\/strong><br><br>Chemotaxis, the directed movement in response to chemical gradients, is a key property of living systems. Reproducing this behavior in minimal synthetic structures provides a unique opportunity to explore the physical mechanisms underlying active navigation. We present the study of enzyme-loaded liposomes exposed to controlled substrate gradients. Upon incorporation of \u03b1-hemolysin pores, enzymatic activity establishes asymmetric product distributions that drive self-diffusiophoretic propulsion. Using microfluidic chemotaxis assays combined with theoretical modeling, we quantify the transition from passive drift to active chemotaxis. These findings establish liposomes as versatile platforms to investigate how chemical reactions and membrane properties couple to directional motion, bridging soft matter physics with active matter. Beyond fundamental insights, this approach outlines a framework for designing stimuli-responsive, self-directed delivery systems with potential applications in precision therapies where navigation toward biochemical signals is critical.<br><br><em>B\u00e1rbara Borges Fernandes obtained a Bachelor\u2019s degree in Chemical Engineering and a Master\u2019s degree in Mechanical Engineering with a specialization in fluid dynamics from the Federal University of Minas Gerais, Brazil. She completed an Erasmus Mundus Master\u2019s in Nanoscience and Nanotechnology at KU Leuven (Belgium) and the University of Barcelona\/IBEC, bridging fluidics and engineering with biomedical applications such as inertial focusing of cells for cancer detection. Currently, B\u00e1rbara is completing a PhD in Physics at IBEC\u2013University of Barcelona, under the supervision of Prof. Giuseppe Battaglia. Her doctoral research combines de novo synthetic biology with out-of-equilibrium physics and active matter principles to study chemotaxis in minimal synthetic systems. Alongside her PhD, she serves as a substitute professor at the University of Barcelona and has initiated a postdoctoral project aimed at developing microfluidic devices for the controlled culture of neural spheres.<\/em><br><br><br><strong>H\u00e9lder A. Santos<\/strong>, Department of Biomaterials and Biomedical Technology, University Medical Center Groningen, University of Groningen, The Netherlands&nbsp;<br><br><strong>RNA-Based Polysaccharide Nanoformulations For Myocardium Infarction Therapy<\/strong><br><br>Cardiovascular diseases (CVDs) remain the leading cause of mortality globally. Nanotechnology has emerged as a transformative strategy for targeted drug delivery via rational design. Yet, challenges persist, such as ischemic myocardium and lesional plaques. To address these, RNA-based nanosystems can be used achieve precise drug delivery towards the conditioning of myocardial ischemic injury and atherosclerosis. Here, I will present our latest works on the application of different nanosystems for myocardium infarction applications. Functional heart evaluation using clinical-relevant murine models were conducted, demonstrating that the nanosystems can mitigate ischemia-reperfusion injury and inflammatory responses. Overall, we have demonstrated that different nanomedicines directed to specific cells and cell-receptors need to be carefully designed and optimized, promoting the development of precision medicine for CVDs, highlighting their clinical translational potential.<br><br><em>Prof. Santos (D.Sc. Tech., Chem. Eng.) is a Full Professor and Chair in Biomedical Engineering, and the Head of the Department of Biomaterials and Biomedical Technology, University Medical Center Groningen, University of Groningen. Prof. Santos is also the co-founder of the startups Capsamedix Oy and Medixmicro Oy, and was the Coordinator of a large MSCA-ITN P4 FIT network in tendon repair using nanomedicines (~ 4.1 m\u20ac). He holds Visiting Professorships at the Shanghai Jiao Tong University School of Medicine and University of Tartu, and he is also an Honorary Adjunct Fellow at the University of Technology Sydney. Prof. Santos research interests include the development of nanoparticles\/nanomedicines and biomaterials for biomedical applications, particularly cancer and heart diseases. Currently, he supervises 25 PhD students and 5 MSCA-postdoctoral fellowships. His lab makes the unique bridge between medical engineering, pharmaceutical nanotechnology, and tissue engineering by combining unique techniques to develop novel therapeutic formulations for translation into the clinic. He is co-author of +550 publications (+31300 citations; h-index = 99) and 8 patents. He has +260 invited talks around the world. He is also in Editorial board member of Advanced Healthcare Materials, Advanced Therapeutics, Chemical Society Reviews, Journal of Controlled Release, VIEW, Journal of Functional Materials, Frontiers in Bioengineering and Biotechnology and Materials, Frontiers in Biomaterials, Precision Nanomedicine, among many others. He is an Associate Editor of Nano Select, Drug Delivery and Translational Research, and Guest Editor for Journal of Controlled Release, among others. Prof. Santos has received prestigious honours, awards and grants, such as the \u00abTalent Prize in Science\u00bb in 2010 attributed by the Portuguese Government, the European Research Council Starting Grant in 2013, the European Research Council Proof-of-Concept Grant in 2018, the Young Researcher Award in 2013 attributed by the University of Helsinki, the Academy of Finland Award for Social Impact in 2016, and the Controlled Release Society Young Investigator Award 2021. Altogether, Prof. Santos has secured since 2009 +35 research grants nationally and internationally worth of +20 M\u20ac.<br>&nbsp;<br><strong>Key publications for this talk:<\/strong><br>\u2022 Qiang Long, Kristina Rabi, Yu Cai, Lihui Li, Shixing Huang, Bei Qian, Yiming Zhong, Zhaoxi Qi, Yecen Zhang, Kaichen Huang, Xinming Wang, Lan Chang, Weichang Xie, Huaiyu Jiang, Haonan Zhang, Junjie Zhang, Ting Ren, Zichen Wang, Tambet Teesalu, Caisheng Wu, Lin Lu, Zhengbin Zhu, Yiwei Chu, <strong>H\u00e9lder A. Santos,<\/strong> Zehua Liu*, Qiang Zhao*, Xiaofeng Ye*,\u00bb<strong>Identification of Splenic IRF7 as a Nanotherapy Target for Tele-Conditioning Myocardial Reperfusion Injury<\/strong>\u00ab, Nat. Commun. 2025, 16, 1909.<br>\u2022 Han Gao, Sen Li, Zhengyi Lan, Da Pan, Gonna Somu Naidu, Dan Peer, Chenyi Ye, Hangrong Chen, Ming Ma*, Zehua Liu*, <strong>H\u00e9lder A. Santos*,<\/strong> \u201c<strong>Comparative Optimization of Polysaccharide-Based Nanoformulations for Cardiac RNAi Therapy<\/strong>\u201d, Nature Commun. 2024, 15, 5398.<br>Paul Joyce*, Christine J. Allen, Mar\u00eda Jos\u00e9 Alonso\u2009, Marianne Ashford, Michelle S. Bradbury\u2009, Matthieu Germain, Maria Kavallaris, Robert Langer, Twan Lammers, Maria Teresa Peracchia, Amirali Popat, Clive A. Prestidge, Cristianne J. F. Rijcken, Bruno Sarmento, Ruth B. Schmid, Avi Schroeder, Santhni Subramaniam, Chelsea R. Thorn, Kathryn A. Whitehead, Chun-Xia Zhao\u2009,&nbsp;<strong>H\u00e9lder A. Santos*<\/strong>, \u00ab<strong>A Translational Framework to DELIVER Nanomedicines to the Clinic<\/strong>\u00ab,&nbsp;Nat. Nanotechnol.&nbsp;<strong>2024<\/strong>,&nbsp;19,&nbsp;1597\u20131611.<br>\u2022 Manlio Fusciello, Flavia Fontana, Siri T\u00e4htinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Yl\u00f6sm\u00e4ki, Erkko Yl\u00f6sm\u00e4ki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, <strong>H\u00e9lder A. Santos*,<\/strong> Vincenzo Cerullo*, \u201c<strong>Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy<\/strong>\u201d, Nature Commun. 2019, 10, 5747.<br>\u2022 Tuying Yong, Xiaoqiong Zhang, Nana Bie, Hongbo Zhang, Xuting Zhang, Fuying Li, Abdul Hakeem, Jun Hu, Lu Gan*, <strong>H\u00e9lder A. Santos*,<\/strong> Xiangliang Yang*, \u201c<strong>Tumor Exosome-Based Nanoparticles are Efficient Drug Carriers for Chemotherapy<\/strong>\u201d, Nature Commun. 2019, 10(1), 3838.<br>\u2022 Wei Li, Jian Chen, Shujie Zhao, Tianhe Huang, Huiyan Ying, Claudia Trujillo, Giuseppina Molinaro, Zheng Zhou, Tao Jiang, Wei Liu, Linwei Li, Yuancheng Bai, Peng Quan, Yaping Ding, Jouni Hirvonen, Guoyong Yin*, <strong>H\u00e9lder A. Santos*,<\/strong> Jin Fan*, Dongfei Liu*, \u201c<strong>High Drug-Loaded Microspheres Enabled by Controlled in-Droplet Precipitation Promote Functional Recovery After Spinal Cord Injury<\/strong>\u201d, Nature Commun. 2022, 13, 1262.<\/em><br><br><br><strong>Juan C. Fraire<\/strong>, Institute for Bioengineering of Catalonia (IBEC) \/ Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)<br><br><strong>Combining nanocarrier design and self-propulsion for delivery of nucleic acids.<\/strong><br><br>Targeting the genetic basis of many diseases is advancing rapidly, as shown by the approval of nucleic-acid therapeutics by the FDA and EMA. Nanocarriers promise to deliver nucleic acids (pDNA, mRNA, siRNA) selectively to target tissues with higher efficacy and fewer side effects, though physiological barriers remain a challenge. Self-propelled nanoparticles or nanomotors (NMs) are emerging as the next generation of nanocarriers. Enzyme-powered NMs are especially promising, as they use physiologically relevant fuels to move under in vivo conditions. Their collective \u201cswarming\u201d behavior has been demonstrated in vitro and in vivo, showing enhanced displacement, convection, and mixing.<br>In this talk, I will present our urease-powered platform based on biocompatible, biodegradable PLGA NPs, used as scaffolds for layer-by-layer (LBL) assembly of nucleic acids-loaded PLGA NMs. This versatile platform can be tuned by varying nucleic acids, polymers (affecting complexation and intracellular release), and enzymes (urease, urease\/collagenase). I will discuss nanocarrier design, functionalization, and evaluation of collective behavior in drug delivery.<br><br><em>Juan Fraire obtained his PhD in Chemistry from the University of C\u00f3rdoba (Argentina) in 2016. Following his PhD, Juan joined the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University (Belgium) as a postdoctoral researcher, where he worked on photoporation as an advanced drug delivery technique for nucleic acid therapeutics and cell transfection. He has been awarded prestigious fellowships, including those from CONICET (Argentina), Fulbright (Boston University, USA), FWO (Ghent University, Belgium), and Beatriu de Pin\u00f3s &#8211; Marie-Curie COFUND (IBEC, Spain). His early-career contributions have been recognized with the Ocean Optics Young Investigator Award and the Sabato Institute Award. In 2021, he joined the Smart Nano-Bio-Devices group at the Institute for Bioengineering of Catalonia (IBEC, Spain), and was promoted to Senior Researcher in 2023. Juan is currently Ramon y Cajal Principal Investigator at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) where he leads the Gene and Light NanoTherapies Lab (frairelab.com). His research interests include rational design of nanocarriers for nucleic acid delivery, the exploitation of light-triggered effects for intracellular delivery and immunogenic activation, and the development of stimuli-responsive nanosystems.<\/em><br><br><br><strong>Victor Puntes<\/strong>, VHIR\/ICN2<br><br><strong>Doping cerium oxide nanocrystals with oxygen vacancies to regulate mitochondrial function in the context of immune exhaustion, loss of immunosurveillance and cancer development.<\/strong> <br><br>Tumors progress because they can escape from the immune system, which is the responsible to remove the tumoral cells that our body normally produces without more consequences. One of the strategies of tumours to elude the immune system control is inflammation. Tumours micro environment is mildly inflamed and in this status cancer cells succeed in hiding from the immune system and avoiding elimination. Therefore, antioxidant therapy can remove the inflammation cloak and expose the cancer to the immune system for its eradication. To do this job, Cerium oxide nanoparticles have raised recently as smart antioxidant agents, which are inactive and slowly dissolves in healthy conditions and are antioxidant (anti-inflammatory and anti-tumoral) in the case of cancer and inflammation. Preliminary results show how the NPs accumulate in the liver, decreases the inflammation, stops tumor proliferation and extend life span of the treated animal models.<br><br><em>Victor Puntes is an ICREA research professor and leader of the nanoparticle pharmacokinetics group at the Vall Hebron Research Institute (VHIR), which focuses his research on the synthesis, functionalization and study of the interactions, applicability and nanotoxicology of nanoparticles in biological contexts. Prof. Puntes graduated in chemical engineering from Louis Pasteur University (Strasbourg) in 1994 and received his PhD in Physics from the University of Barcelona in 1998. Between 2000 and 2004, he held a postdoctoral position as a postdoctoral researcher at the University of California-Berkeley (UCB) and the Lawrence Berkeley National Laboratory (LBNL), in the groups of Prof. Paul Alivisatos and Prof. Kannan Krishnan where he trained in the field of magnetic nanoparticle synthesis. In 2003 he obtained a position as a Ram\u00f3n y Cajal researcher at the University of Barcelona. In 2005 he created the Inorganic Nanoparticles Group at the ICN2 and in 2015 the Design and pharmaciokinetics of nanoparticles laboratory at VHIR. Since January 2022, he is also a member of the Network Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).<\/em><br><br><br><strong>Cristina Fornaguera,<\/strong> Institut Qu\u00edmic de Sarri\u00e0 (IQS), Universitat Ramon Llull (URL)<br><br><strong>Overcoming Biological Barriers: RNA Delivery via Poly(\u03b2-amino ester) Nanocarriers<\/strong><br><br>Poly(\u03b2-amino ester) (pBAE) nanoparticles have emerged as promising vehicles for RNA delivery due to their biocompatibility, tunable structure, and efficient transfection capabilities. Our research has demonstrated the potential of pBAEs to deliver therapeutic RNA molecules\u2014such as mRNA and siRNA\u2014to target cells, including dendritic cells and tumor cells, with enhanced efficiency and safety. However, effective in vivo application of RNA nanomedicines requires more than cargo protection and intracellular delivery: it demands a precise understanding of how nanoparticles interact with and traverse physiological barriers, such as mucus layers, endothelium, and the extracellular matrix. In our latest studies, we have engineered surface-modified pBAE nanoformulations to improve penetration across these barriers, with a special focus on pulmonary, tumor, and lymphoid microenvironments. By integrating physicochemical design with biological insight, we aim to rationally guide nanocarriers through complex biological interfaces, ultimately enhancing therapeutic efficacy and translational impact.<br><br><em>Cristina Fornaguera is an associate professor at IQS-URL, holding the ICREA Academia recognition since 2024. She is a biotechnologist, specialized in nanomedicine and pharmaceutical technology, with broad experience in drug and gene delivery systems. Her current research aims to tackle cancer and neural diseases, among other unmet medical needs, ever-demanding challenges, by developing innovative smart targeted nano\/micro (bio)materials. Her research group is focused on the design of proprietary polymers for the further formulation of polymeric NP encapsulating nucleic acids, selectively targeted to different cells of interest. Among the different unmet medical needs, her group aims to design complex nanosystems that can make cancer immunotherapy the standard of care in the near future. They aim at the development of formulations with a special focus on the controlled interaction with physiological barriers. She currently leads a group of more than 30 researchers, has been funded by many national and international funding agencies, and has published more than 50 papers in high-impact peer-reviewed journals.<\/em><br><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h6 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\">Workshop 4: <strong>Towards clinical translation<\/strong><\/h6>\n<div class=\"trigger-plus-minus\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p style=\"margin-top:0;margin-bottom:0\">Date and venue<\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\">Friday 08\/05\/2025 \u00b7 08:15h &#8211; 16:15h<\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\">Dolors Aleu Room, Cluster II (PCB)<br><\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\">The <strong>Next-Generation Nanomedicine Network (NET-NANO) <\/strong>is hosting its fourth workshop on <strong>May 8<sup>th<\/sup><\/strong>, focusing on the theme of <strong>clinical translation<\/strong>. This event will address the critical challenges of bridging the <em>in vitro<\/em>-to-<em>in vivo <\/em>and bench-to-clinic gaps.<\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\"><\/p>\n\n\n\n<p>We are honoured to welcome <strong>Prof. Twan Lammers<\/strong> (RWTH Aachen University Clinic, Germany) as our Plenary Speaker. The workshop will also feature talks from both internal IBEC researchers and leading external experts, including <strong>Dr Ibane Abasolo <\/strong>(IQAC-CSIC), <strong>Dr Marta Soler <\/strong>(Nanobots Therapeutics), and <strong>Dr Judit Morl\u00e0-Folch <\/strong>(ICMAB-CSIC), bringing together a diverse range of perspectives on clinical translation and entrepreneurship, including experience in founding spin-off companies.<\/p>\n\n\n\n<p style=\"margin-top:0;margin-bottom:0\">Join us for a day of insightful presentations, a challenge board, and a roundtable discussion designed to network and explore the future of nanomedicine. This event will be particularly interesting for PhD students and Postdocs eager to explore the world beyond pure academia, or for anyone with a great taste for science and innovation and a willingness to have a good time.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Scheduled programme<\/strong><\/p>\n\n\n\n<p><strong>09:15-09:30<\/strong> Registration<br><br><strong>09:30-09:40<\/strong> Welcome from Network Coordinator<br><br><strong>09:40-10:15<\/strong> Dr Rosalba Sortino (Nanoprobes and Nanoswitches, IBEC) \u2013 \u201cRestoring vision: from fundamental research to therapeutic strategies\u201d<br><br><strong>10:15-10:50<\/strong> Eul\u00e0lia Negre (Nanobioengineering, IBEC) \u2013 \u201cAdvancing Clinical Translation: A Scalable Blood-Brain Barrier-on-a-Chip Model for Nanomedicine and Drug Testing\u201d<br><br><strong>10:50-11:25<\/strong> Coffee Break &amp; Challenge Board<br><br><strong>11:25-12:00<\/strong> Prof. Samuel S\u00e1nchez and Dr. Marta Soler (IBEC and Nanobots Therapeutics) \u2013 \u201cNanobots: Therapeutics in Motion\u201d<br><br><strong>12:00-12:35<\/strong> Invited Speaker: Dr Judit Morl\u00e0-Folch (NANOMOL-Bio, ICMAB-CSIC) \u2013 \u201cNanomaterials for Advanced Nanopharmaceuticals: Progress toward Clinical Translation\u201d<br><br><strong>12:35-13:10<\/strong> Prof. Giuseppe Battaglia (Molecular Bionics, IBEC) \u2013 \u201cThe evolution of nanomedicine from drug delivery to drug design: A short story of translating science into advanced therapy\u201d<br><br><strong>13:10-14:00<\/strong> Networking Lunch<br><br><strong>14:00-14:35<\/strong> Invited Speaker: Dr Ibane Abasolo (Nanomaterials for Therapeutic Applications, IQAC-CSIC) \u2013 \u201cIron Oxide Nanoparticles for Magnetic Hyperthermia in Pancreatic Cancer: Translational Lessons from Preclinical Development\u201d<br><br><strong>14:35-15:35<\/strong> Plenary Speaker: Twan Lammers (RWTH Aachen University Clinic, Germany) \u2013 \u201cHow to Promote Cancer Nanomedicine Clinical Translation\u201d<br><br><strong>15:35-16:05<\/strong> Roundtable Discussion<br><br><strong>16:05-16:15<\/strong> Farewell from Network Representatives<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p>Plenary talk details:<\/p>\n\n\n\n<p><strong>How to Promote Cancer Nanomedicine Clinical Translation<\/strong><\/p>\n\n\n\n<p>Twan Lammers, RWTH Aachen University Clinic, Germany<br><\/p>\n\n\n\n<p>Nanomedicines are extensively used for cancer therapy. By delivering drug molecules more effectively and more selectively to pathological sites, nanomedicines assist in improving the balance between drug efficacy and toxicity. The tumor accumulation of nanomedicines is traditionally ascribed to the EPR effect, which is highly variable, both in animal models and in patients. To address issues associated with tumor targeting heterogeneity, and to promote cancer nanomedicine clinical translation, we are developing tools and technologies to monitor and modulate tumor-targeted drug delivery. In the present lecture, several of these strategies will be highlighted, including the use of imaging and histopathology biomarkers for patient stratification, and physical, pharmacological and physiological interventions to prime the tumor microenvironment for better delivery. Together, our work aims to establish rational and realistic ways forward to improve the clinical impact of cancer nanomedicines.<\/p>\n\n\n\n<p><em>Twan Lammers obtained a D.Sc. in Radiation Oncology from Heidelberg University in 2008 and a Ph.D. in Pharmaceutical Technology from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at RWTH Aachen University. In 2014, he was promoted to full professor of medicine at RWTH Aachen University Clinic. His group aims to individualize and improve disease treatment by combining drug targeting with imaging. To this end, image-guided (theranostic) drug delivery systems are being developed, as well as materials and methods to monitor tumor growth, angiogenesis, inflammation, fibrosis and metastasis. He has received multiple scholarships and awards, including ERC starting, consolidator and proof-of-concept grants, and the CRS Young Investigator and Exceptional Leadership Awards. Lammers was president of the Controlled Release Society in 2024 and currently serves as secretary of the European Society for Molecular Imaging. He has published &gt; 350 papers (h-index = 103) and has been is included in the Clarivate Analytics list of Highly Cited Researchers. He is a on the editorial board of &gt;10 journals, and acts as associate editor for JCR, DDTR and MIB.<\/em><\/p>\n\n\n\n<p><br><strong>Iron Oxide Nanoparticles for Magnetic Hyperthermia in Pancreatic Cancer: Translational Lessons from Preclinical Development<\/strong><\/p>\n\n\n\n<p>Ibane Abasolo,<em> Nanomaterials for Therapeutic Applications, IQAC-CSIC<\/em><\/p>\n\n\n\n<p><br>Pancreatic ductal adenocarcinoma is characterized by a dense desmoplastic stroma that limits drug penetration and contributes to the poor efficacy of chemotherapy. Magnetic hyperthermia mediated by iron oxide nanoparticles offers a locoregional strategy to generate heat within the tumour.<br>This talk will summarize the translational development of the NoCanTher ThermoTherapy approach, based on intratumoral administration of a sterile magnetic fluid composed of iron oxide nanoparticles combined with gemcitabine and nab-paclitaxel. Preclinical studies demonstrated synergy between chemotherapy and magnetic hyperthermia, tumour retention of the nanoparticles, improved drug penetration, and reduced tumour volume versus chemotherapy alone. I will also present the first clinical experience from the NoCanTher study, including the six patients treated. As the first clinical study of magnetic hyperthermia in pancreatic cancer, NoCanTher represents an important translational milestone. The experience gained helps refine administration, image-guided planning, monitoring, and temperature modelling, supporting the continued development of magnetic hyperthermia for pancreatic cancer.<\/p>\n\n\n\n<p><em>Ibane Abasolo, PhD, is a Research Scientist at the Institute of Advanced Chemistry of Catalonia [IQAC-CSIC], where she leads the Nanomaterials for Therapeutic Applications group. She also leads a CIBER-BBN group focused on the development of nanomedicines for cancer and rare diseases.<br>Her research is centred on the translational development of advanced drug delivery systems, including iron oxide nanoparticles, liposomes and extracellular vesicle-based platforms. Her work spans nanosystem design, biological characterization, preclinical validation and clinical-oriented development, with a strong emphasis on therapeutic applicability and patient impact. Before joining CSIC, she spent over 16 years at Vall d\u2019Hebron Research Institute, where she led research on drug delivery and targeted therapies in close interaction with clinicians, hospitals, biotech companies and European consortia. She has contributed to the development of more than 20 therapeutic candidates, including nanoparticle-based approaches for oncology and rare diseases. Among these, she played a key role in the translational development of magnetic hyperthermia using iron oxide nanoparticles for pancreatic cancer, contributing to the first clinical study of magnetic hyperthermia in this indication.<br>Dr. Abasolo has led or coordinated multiple national and European projects, contributed to more than 80 scientific publications, and is inventor on four patents, one of them transferred to industry. Her work combines applied nanomedicine, preclinical models, technology transfer and clinical translation, with the aim of advancing innovative therapies towards real therapeutic benefit.<\/em><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Nanomaterials for Advanced Nanopharmaceuticals: Progress toward Clinical Translation<\/strong><\/p>\n\n\n\n<p>Judit Morl\u00e0 Folch, Institut de Ci\u00e8ncia dels Materials de Barcelona (ICMAB-CSIC)<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Fabry disease, a lysosomal storage disorder caused by deficient \u03b1-galactosidase A (GLA), remains inadequately treated by current enzyme replacement therapies (ERT) due to limited biodistribution and lack of CNS targeting. To overcome these barriers, we developed nanoGLA, an RGD-functionalized nanoliposomal GLA formulation, produced using the scalable, eco-friendly and GMP-compatible DELOS technology. Comprehensive characterization established robust critical quality attributes (CQAs) and ensured batch-to-batch consistency from laboratory to preclinical scale. In preclinical studies with the Fabry animal models (GLA-deficient mice), nanoGLA demonstrated enhanced plasma exposure, improved tissue biodistribution, and superior efficacy in multiple organs, including the brain, compared with conventional ERT. Its translation potential is further supported by the EMA\u2019s Orphan Drug Designation, and successful\u00a0 advancement into a non-rodent model (minipig), where initial pharmacokinetic and tolerability studies showed promising feasibility. Together, these results position nanoGLA as a clinically translatable next-generation therapy for Fabry disease and illustrate a scalable nanomedicine strategy to address unmet challenges in lysosomal storage disorders.<br><br><em>Dr. Judit Morla-Folch is a Ramon y Cajal researcher at the Institute of Materials Science of Barcelona (ICMAB-CSIC). Her research focuses on the development of organic-based nanomaterials development for biomedical applications, including therapeutic and imaging strategies.<br>She graduated in Biotechnology from the University Rovira i Virgili of Tarragona (URV, Spain) and obtained her PhD in Nanoscience, Materials and Chemical Engineering in 2017 (URV). Her doctoral research focused on the analysis of nucleic acids using direct label-free surface-enhanced Raman Scattering (SERS). Following a research stay at the Nanyang Technological University in Singapore, she worked in the private sector as Innovation Manager, focusing on strengthening the bridge between academic research and industry in the health care sector. In 2018, she returned to academia after receiving the competitive Marie Curie Tecniospring+ Postdoctoral Fellowship, leading a collaborative project between the New Jersey Institute of Technology (New Jersey, USA) and ICMAB-CSIC (Barcelona, Spain) focused on the development of ultrabright fluorescent nanoprobes for bioimaging.<br>In 2021, she joined the Nanomedicine Lab at Mount Sinai Hospital (New York City, USA) where she combined her expertise in nanomaterials with the lab\u2019s work on immune modulation through nanotherapeutics. Prior joining ICMAB as a Ramon y Cajal researcher, she became part of the Nano4Rare team, an EU-funded project (EIC Transition), as preclinical researcher. In this role, she supported the advancement of nanoGLA, the project\u2019s lead nanomedicine candidate, through preclinical development toward first-in-human studies, coordinating timelines, resources and translational activities.<\/em><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Nanobots: Therapeutics in Motion<\/strong><\/p>\n\n\n\n<p>Samuel S\u00e1nchez and Marta Soler, <em>IBEC and Nanobots Therapeutics<\/em><br><\/p>\n\n\n\n<p>Engineering medical nanomotors\/nanobots will imply the use of biocompatible materials and bio-friendly propulsion mechanisms. Our strategy comprises the use of biocatalysts such enzymes for converting biologically available fuels into a propulsive force. Moreover, nanoparticles\u2019 chassis are generally recognized as safe (GRAS) material, FDA or EMA approved materials.<br>In my talk, I will present how we bioengineer hybrid nanobots combining the best from the two worlds: biology (enzymes) and (nano)technology (nano- micro-particles) providing swimming capabilities, biocompatibility, imaging, multifunctionality and actuation in vitro and in vivo. I will present some of the proof-of-concept applications of biocompatible nanobots such as the efficient transport of drugs into cancer cells and 3D spheroids (1), the imaging of swarms of nanobots in vivo in confined spaces like the bladder of living mice (2). Moreover, I will present our recent advances in the treatment of bladder cancer in mice using radionuclide-labelled nanobots (3) and STING agonist (4). Nanobots are actively crossing mucus layers present in the colon of mice (5), synovial fluids of joints (6), the vitreous or the skin.<br>In this talk we will present the origin, journey, and future steps of Nanobots Therapeutics. Our goal is to offer new therapeutic solutions for oncology by developing MotionTx, a platform of enzymatic self-propelled nanobots that efficiently delivery a variety of therapeutic cargos which have shown promising efficacy in mouse models of bladder cancer.<\/p>\n\n\n\n<p>References<br>[1] Hortelao et al. ACS Nano 2019, 13, (1), 429-439<br>[2] Hortelao et al. Sci. Robotics. 2021, 6, (52), eabd2823.<br>[3] C. Sim\u00f3, M. Serra et al. Nat. Nanotech. 2024, 19, 554\u2013564<br>[4] H. Choi et al. Nat. Commun. 2024, 15 (1), 9934<br>[5] M. Serra et al. ACS Nano. 2024, 18, 16701-16714<br>[6] N. Ruiz-Gonz\u00e1lez et al. Small 2024, 20 (11), 2309387<\/p>\n\n\n\n<p><em>Prof. Samuel S\u00e1nchez Ord\u00f3\u00f1ez is an ICREA Research Professor and Group Leader at the Institute for Bioengineering of Catalonia (IBEC), where he also serves as Deputy Director for Internationalization. Samuel has had an international career in different research centers between Japan and Germany, including Max Planck for Intelligent Systems. He leads the Smart Nano-Bio-Devices group, pioneering self-powered nanorobots, nanomedicine, and biohybrid robotics. His team achieved the first in vivo imaging of nanobots and recently demonstrated their therapeutic potential against bladder cancer (Nature Nanotechnology, 2024). He has authored 200+ publications, with an h-index of 84 and over 23,000 citations. He filed 9 patents. Samuel is founder and CSO of Nanobots Therapeutics, which drives the MotionTx platform for next-generation cancer treatments. He has received major awards, including the MIT TR35 Innovator of the Year (2014), Princess of Girona Award (2015), National Research Award for Young Talent (2016), RSEQ Scientific Excellence Award (2022), and the Constantes y Vitales Award Young talent in Biomedicine (2023). His work in Nature Nanotechnology has been selected as top3 research output in Spain by La Vanguardia Newspaper and appeared in National Geographic in October 2024.<\/em><\/p>\n\n\n\n<p><em><br>Marta Soler is the CEO of Nanobots Therapeutics, a biotech spin-off focused on developing novel therapies for oncology. She holds a PhD in molecular oncology from the University of Barcelona and has built her career at the intersection of research, innovation, and business.<br>Before leading Nanobots, she worked in scouting and evaluation of therapeutic assets at Ferrer and spent several years at Biocat, where she supported innovation, technology transfer, and collaboration with startups and investors in the biotech ecosystem. She also has earlier experience in scientific management and European research projects.<\/em><\/p>\n\n\n\n<p><strong>The evolution of nanomedicine from drug delivery to drug design: A short story of translating science into advanced therapy<\/strong><\/p>\n\n\n\n<p>Giuseppe Battaglia, <em>Institute for Bioengineering of Catalonia<\/em><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>I will discuss how nanotechnology has evolved from a vehicle for delivering drugs and gene therapies into a sophisticated means of controlling biological processes at an unprecedented scale. I will focus on my work using polymersomes, nanoscopic, synthetic vesicles formed by the self-assembly of amphiphilic block copolymers. Unlike their lipid-based counterparts, these robust vesicles offer superior stability and a highly tunable surface, making them an ideal nanomedicine tool. I will show how we are transforming these systems from simple carriers into \u00absupramolecular drugs\u00bb by leveraging unique features that emerge at the nanoscale. By orchestrating multivalency and the precise control of endocytosis, we can design nanoparticles that interact with cellular machinery to restore loss function. Throughout this discussion, I will explain the fundamental science behind these advancements while sharing the story of how we translate these laboratory discoveries into spin-out companies to push these therapies toward the clinic.<br><br><em>Giuseppe Battaglia is an ICREA Professor and founder of the Molecular Bionics Group at the Institute for Bioengineering of Catalonia (IBEC), where he also serves as the Associate Director for Valorisation and the Scientific Coordinator of Nanomed Spain. He holds the honorary title of Professor of Biophysical Chemistry at University College London (UCL) and is a Visiting Professor at the West China Hospital, Sichuan University. He holds a Laurea in Chemical Engineering from the University of Palermo and a PhD in Physical Chemistry from the University of Sheffield, and prior to his move to Barcelona, he held the Professorship in Molecular Bionics at UCL and in Synthetic Biology at the University of Sheffield.<br>Operating at the interface of soft matter physics and synthetic chemistry, Professor Battaglia\u2019s research investigates molecular and cellular trafficking across biological barriers, most notably the blood-brain barrier. He is a pioneer in the engineering of polymersomes, robust, nanoscopic vesicles formed by the self-assembly of amphiphilic block copolymers. His work has fundamentally redefined these systems, evolving them from simple delivery vehicles into \u00absupramolecular drugs\u00bb that leverage multivalency and endocytosis control to modulate biological function at the nanoscale.<br>A Fellow of the Royal Society of Chemistry (FRSC), the Royal Society of Biology (FRSB), and the Institute of Materials, Minerals and Mining (FIMMM), his career is marked by multiple ERC grants and the McBain Medal. Beyond the laboratory, Professor Battaglia is a dedicated advocate for clinical translation, bridging fundamental biophysics with the creation of spin-out companies to accelerate the transition of transformative nanomedicines from bench to bedside<\/em><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Restoring vision: from fundamental research to therapeutic strategies<\/strong><\/p>\n\n\n\n<p>Rosalba Sortino, <em>Institute for Bioengineering of Catalonia<br><\/em><\/p>\n\n\n\n<p>Blinding diseases due to degeneration of photoreceptors (PhRs) like retinitis pigmentosa leave the rest of the retinal circuitry largely intact, albeit unable to respond to light. Current approaches, including gene therapy and retinal prostheses, are limited by mutation specificity, invasiveness, or restricted functional outcomes. Photopharmacology can develop photoswitchable small molecules to restore vision impairment by conferring light sensitivity to ion channels that are widely expressed in the remaining inner retinal neurons, and a first-in-human clinical trial is ongoing. We have developed novel photoswitchable small molecule ligands of metabotropic glutamate 6 (mGlu6) receptors, which are located exclusively at the dendrites of ON bipolar cells (postsynaptic to PhRs) and can leverage a privileged position to mimic physiological signals in the remnant retinal circuit. These compounds (prosthe6) thus act as &#8216;molecular prostheses&#8217; that can restore the light input to the retina via upstream-targeted control of the circuit after PhRs degeneration. Ongoing translational efforts focus on formulation, regulatory pathways, and progression toward first-in-human clinical trials.<br><\/p>\n\n\n\n<p><em>Rosalba Sortino holds a strong academic background in Biotechnology, having obtained both her Bachelor\u2019s and Master\u2019s degrees in Medical Biotechnology and Molecular Biology from the University of Palermo. Her PhD research at the Institute for Bioengineering of Catalonia focused on photopharmacology, where she tested photoswitchable ligands both in vitro and in vivo to control G protein-coupled receptors with light. This work led to innovative strategies for modulating neuronal activity in living systems, including the first demonstration of three-photon neurostimulation in vivo.<br>She completed her PhD in Biotechnology at the Universitat de Barcelona in October 2023, with a thesis titled Development and Applications of Photoswitchable Ligands for G Protein-Coupled Receptors, graduating with an Excellent Cum Laude distinction. Her scientific career has been marked by international and interdisciplinary experience, including an internship at King\u2019s College London. Currently a postdoctoral researcher, she continues to advance the optical control of neuronal receptors using cutting-edge microscopy and pharmacological tools. Over the course of her career, she has authored more than 10 scientific publications in high-impact journals, several as first or co-first author, presented her work at international conferences, and contributed to ongoing patent applications. In addition to her research achievements, she has demonstrated strong mentorship by guiding more than 10 bachelor and master\u2019s thesis students. Her work bridges fundamental neuroscience and translational applications, particularly in the development of light-based therapies for neurological and visual disorders, reflecting both scientific excellence and a strong commitment to innovation and societal impact.<\/em><br><\/p>\n\n\n\n<p><strong>Advancing Clinical Translation: A Scalable Blood-Brain Barrier-on-a-Chip Model for Nanomedicine and Drug Testing<\/strong><\/p>\n\n\n\n<p>Eul\u00e0lia Negre, <em>Institute for Bioengineering of Catalonia (IBEC)<\/em><br><\/p>\n\n\n\n<p>The development of effective therapies for neurological disorders is heavily hindered by the blood-brain barrier (BBB), which restricts the delivery of most drugs and nanomedicines to the brain. To bridge the gap between conventional cell culture and animal testing, we present a cutting-edge BBB-on-a-chip (BBBoC) model. Our platform focuses on clinical translation by offering a scalable, industry-ready solution for pharmaceutical validation. Currently, we are utilizing the device to test both novel nanomedicines and existing market drugs to demonstrate its robustness and permeability assessment capabilities through HPLC-MS and advanced microscopy. Furthermore, the versatility of this chip has been explored in specialized studies, such as the effects of hypergravity on barrier integrity. Future developments aim to incorporate patient-derived cells and disease-specific models to evaluate personalized responses to treatments. This organ-on-a-chip approach provides a high-fidelity alternative for preclinical testing, accelerating the path from the lab to the clinic.<\/p>\n\n\n\n<p><br><em>Eul\u00e0lia Negre is a Laboratory Technician in the Nanobioengineering Group at the Institute for Bioengineering of Catalonia (IBEC), specializing in microfluidics and organ-on-a-chip technologies. She holds a degree in Chemical Engineering, during which she conducted a 6-month research stay at Chalmers University of Technology (Sweden) focused on microfluidics and biosensors. She further specialized with a Master\u2019s degree in Biomedical Engineering, completing her thesis at IBEC on the effects of hypergravity on Blood-Brain Barrier-on-a-chip (BBBoC) models.<br>Currently, she is a key member of the iNN2Brain project, funded by the CaixaImpulse Programme and led by Dr. Anna Lagunas and Dr. M\u00f2nica Mir. Her work focuses on the fabrication of microfluidic devices and the optimization of BBBoC models to transform how brain-targeting therapies are tested. Her expertise includes cell culture, permeability assays, and advanced imaging techniques (confocal and epifluorescence microscopy), all dedicated to creating scalable, industry-ready platforms that can complement or replace traditional animal testing in the pharmaceutical pipeline.<\/em><\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n<p><\/p>\n\n\n\n<p>Final retreat: the aim is to select the final project and to discuss on future directions to foster continued collaboration beyond the original network scope.&nbsp;<\/p>\n\n\n\n<p>All IBEC groups are welcome to join the network and actively participate by sharing their insights.&nbsp;<\/p>\n\n\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanomedicine represents a paradigm shift in healthcare, offering tailored and sophisticated diagnostic, imaging, and therapeutic solutions for unmet medical needs. This network unites an interdisciplinary team of 9 IBEC groups, &#8230; <a title=\"Next-Generation Nanomedicine (NET-NANO)\u00a0\" class=\"read-more\" href=\"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/\" aria-label=\"More on Next-Generation Nanomedicine (NET-NANO)\u00a0\">Read more<\/a><\/p>\n","protected":false},"author":26,"featured_media":121695,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"tags":[],"class_list":["post-128208","page","type-page","status-publish","has-post-thumbnail"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Next-Generation Nanomedicine (NET-NANO)\u00a0 - Institute for Bioengineering of Catalonia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Next-Generation Nanomedicine (NET-NANO)\u00a0 - Institute for Bioengineering of Catalonia\" \/>\n<meta property=\"og:description\" content=\"Nanomedicine represents a paradigm shift in healthcare, offering tailored and sophisticated diagnostic, imaging, and therapeutic solutions for unmet medical needs. This network unites an interdisciplinary team of 9 IBEC groups, ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/\" \/>\n<meta property=\"og:site_name\" content=\"Institute for Bioengineering of Catalonia\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T06:23:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1276\" \/>\n\t<meta property=\"og:image:height\" content=\"546\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"48 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/\",\"url\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/\",\"name\":\"Next-Generation Nanomedicine (NET-NANO)\u00a0 - Institute for Bioengineering of Catalonia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibecbarcelona.eu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/net-nano-bg.jpg\",\"datePublished\":\"2024-11-21T08:02:13+00:00\",\"dateModified\":\"2026-05-07T06:23:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibecbarcelona.eu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/net-nano-bg.jpg\",\"contentUrl\":\"https:\\\/\\\/ibecbarcelona.eu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/net-nano-bg.jpg\",\"width\":1276,\"height\":546},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/next-generation-nanomedicine-net-nano\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ibecbarcelona.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Next-Generation Nanomedicine (NET-NANO)\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/#website\",\"url\":\"https:\\\/\\\/ibecbarcelona.eu\\\/\",\"name\":\"Institute for Bioengineering of Catalonia\",\"description\":\"Bioengineering solutions for health\",\"publisher\":{\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibecbarcelona.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/#organization\",\"name\":\"Institute for Bioengineering of Catalonia\",\"url\":\"https:\\\/\\\/ibecbarcelona.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ibecbarcelona.eu\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/cropped-IBEC_20ANYS_GRIS.png\",\"contentUrl\":\"https:\\\/\\\/ibecbarcelona.eu\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/cropped-IBEC_20ANYS_GRIS.png\",\"width\":696,\"height\":257,\"caption\":\"Institute for Bioengineering of Catalonia\"},\"image\":{\"@id\":\"https:\\\/\\\/ibecbarcelona.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Next-Generation Nanomedicine (NET-NANO)\u00a0 - Institute for Bioengineering of Catalonia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/","og_locale":"es_ES","og_type":"article","og_title":"Next-Generation Nanomedicine (NET-NANO)\u00a0 - Institute for Bioengineering of Catalonia","og_description":"Nanomedicine represents a paradigm shift in healthcare, offering tailored and sophisticated diagnostic, imaging, and therapeutic solutions for unmet medical needs. This network unites an interdisciplinary team of 9 IBEC groups, ... Read more","og_url":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/","og_site_name":"Institute for Bioengineering of Catalonia","article_modified_time":"2026-05-07T06:23:37+00:00","og_image":[{"width":1276,"height":546,"url":"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"48 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/","url":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/","name":"Next-Generation Nanomedicine (NET-NANO)\u00a0 - Institute for Bioengineering of Catalonia","isPartOf":{"@id":"https:\/\/ibecbarcelona.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/#primaryimage"},"image":{"@id":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/#primaryimage"},"thumbnailUrl":"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg","datePublished":"2024-11-21T08:02:13+00:00","dateModified":"2026-05-07T06:23:37+00:00","breadcrumb":{"@id":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/#primaryimage","url":"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg","contentUrl":"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg","width":1276,"height":546},{"@type":"BreadcrumbList","@id":"https:\/\/ibecbarcelona.eu\/es\/next-generation-nanomedicine-net-nano\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ibecbarcelona.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Next-Generation Nanomedicine (NET-NANO)\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/ibecbarcelona.eu\/#website","url":"https:\/\/ibecbarcelona.eu\/","name":"Institute for Bioengineering of Catalonia","description":"Bioengineering solutions for health","publisher":{"@id":"https:\/\/ibecbarcelona.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibecbarcelona.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ibecbarcelona.eu\/#organization","name":"Institute for Bioengineering of Catalonia","url":"https:\/\/ibecbarcelona.eu\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ibecbarcelona.eu\/#\/schema\/logo\/image\/","url":"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2026\/01\/cropped-IBEC_20ANYS_GRIS.png","contentUrl":"https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2026\/01\/cropped-IBEC_20ANYS_GRIS.png","width":696,"height":257,"caption":"Institute for Bioengineering of Catalonia"},"image":{"@id":"https:\/\/ibecbarcelona.eu\/#\/schema\/logo\/image\/"}}]}},"AFP_featured_media_urls":{"full":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg",1276,546,false],"thumbnail":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-150x150.jpg",150,150,true],"medium":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-300x128.jpg",300,128,true],"medium_large":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-768x329.jpg",768,329,true],"large":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-1024x438.jpg",1024,438,true]},"AFP_attachments":{"full":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg.jpg",1276,546,false],"thumbnail":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-150x150.jpg",150,150,true],"medium":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-300x128.jpg",300,128,true],"medium_large":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-768x329.jpg",768,329,true],"large":["https:\/\/ibecbarcelona.eu\/wp-content\/uploads\/2024\/11\/net-nano-bg-1024x438.jpg",1024,438,true]},"AFP_videos":[],"AFP_video_blocks":"","AFP_category_names":[],"_links":{"self":[{"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/pages\/128208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/comments?post=128208"}],"version-history":[{"count":24,"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/pages\/128208\/revisions"}],"predecessor-version":[{"id":133564,"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/pages\/128208\/revisions\/133564"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/media\/121695"}],"wp:attachment":[{"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/media?parent=128208"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibecbarcelona.eu\/es\/wp-json\/wp\/v2\/tags?post=128208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}